Home/Filings/4/0001209191-14-076841
4//SEC Filing

AVANIR PHARMACEUTICALS, INC. 4

Accession 0001209191-14-076841

CIK 0000858803operating

Filed

Dec 17, 7:00 PM ET

Accepted

Dec 18, 8:55 PM ET

Size

17.3 KB

Accession

0001209191-14-076841

Insider Transaction Report

Form 4
Period: 2014-12-16
OCAMPO CHRISTINE
Vice President, Finance
Transactions
  • Exercise/Conversion

    Common Stock

    2014-12-16$2.59/sh+12,500$32,375127,077 total
  • Sale

    Common Stock

    2014-12-18$16.93/sh5,780$97,855108,797 total
  • Sale

    Common Stock

    2014-12-16$16.94/sh12,500$211,750132,077 total
  • Exercise/Conversion

    Common Stock

    2014-12-16$4.18/sh+17,500$73,150144,577 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2014-12-1612,50017,500 total
    Exercise: $2.59Exp: 2022-12-17Common Stock (12,500 underlying)
  • Sale

    Common Stock

    2014-12-16$16.94/sh17,500$296,450114,577 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2014-12-1617,5000 total
    Exercise: $4.18Exp: 2020-12-01Common Stock (17,500 underlying)
Footnotes (6)
  • [F1]Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
  • [F2]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. A majority of the proceeds from the sales will be used to pay required withholdings due by the Reporting Person for vesting RSUs.
  • [F3]Represents the weighted-average price at which shares were sold within a range between $16.92 and $16.95. The reporting persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]Represents the weighted-average price at which shares were sold within a range between $16.93 and $16.95. The reporting persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F5]The option was granted on 12/17/2012 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.
  • [F6]The option was granted on 12/1/2010 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.

Issuer

AVANIR PHARMACEUTICALS, INC.

CIK 0000858803

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000858803

Filing Metadata

Form type
4
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 8:55 PM ET
Size
17.3 KB